Vermillion Posts 6 Percent Rise in Q2 Revenues, Halts OVA2 Development
August 17, 2012
Vermillion Posts 6 Percent Rise in Q2 Revenues, Halts OVA2 Development
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- UPDATE: Vermillion Repays Quest $5.9M, Ending Companies' Credit Agreement
October 19, 2012 / ProteoMonitor - Vermillion's Q1 Revenues Decline 28 Percent, CEO Page Stepping Down
May 18, 2012 / ProteoMonitor - Vermillion Planning Layoffs, Seeking New Partnerships in 2012
January 6, 2012 / ProteoMonitor - Vermillion Buys Correlogic's Assets for $435K; Correlogic Settles with LabCorp, Quest
November 11, 2011 / ProteoMonitor - FDA Grants Fujirebio 510(k) Approval for ROMA Ovarian Cancer Dx, Potential Rival to Vermillion's OVA1
September 9, 2011 / ProteoMonitor